Update Note: This article reports new analysis involving the federal hepatitis B birth-dose change following Nature World News' earlier coverage of the state lawsuit and modeling study. Latest verified information: Annals of Internal Medicine study published Oct. 19, 2026; Live Science report published Oct. 27, 2026; court status as reported through Oct. 29, 2026.

The fight over the hepatitis B birth dose often sounds like a debate about choice. Doctors who oppose ending the universal shot say it is really about something else — a safety net. Even when the system works as designed, some mothers are never tested, some results are wrong or arrive late, and some babies are exposed at home after birth. The birth dose, given within 24 hours of delivery, is meant to protect newborns in all of those cases.

That concern explains why a new modeling study in the Annals of Internal Medicine has drawn so much attention. It projects sharply more chronic infections among U.S. children if the universal birth dose is replaced, with the largest increases when the decision is left to individual families and providers.

For expectant parents, the practical status is clear for now. A federal court paused the change in March, so the universal birth-dose recommendation remains in effect while the legal fight continues.

What the Proposed Change Would Do

Since 1991, the CDC has recommended that all medically stable newborns receive a first dose of hepatitis B vaccine shortly after birth. In December 2025, the CDC's Advisory Committee on Immunization Practices voted to end that universal recommendation, and the CDC accepted it.

Under the new approach, babies of mothers who test positive for hepatitis B, or whose status is unknown, would still get the birth dose. For mothers who test negative, parents and doctors would decide together whether to give it, which the CDC calls shared clinical decision-making. Babies who skip the birth dose would start the series no earlier than 2 months of age.

That is the strongest argument for the change. Supporters, including former acting CDC Director Jim O'Neill, have said newborns of mothers who test negative face little risk, and the Department of Health and Human Services has framed the policy as respecting parental choice.

The change has not taken effect. On March 16, 2026, a federal judge in Massachusetts stayed it, along with the reconstituted committee's other votes. Nature World News previously reported on the widening state lawsuit and the modeling study, noting that the federal appeal was argued Oct. 6 with no ruling reported as of Oct. 29.

Why the Screening Net Has Holes

The science behind the alarm is about age. When hepatitis B infection happens in infancy or early childhood, more than 90% of cases become chronic, according to Live Science's summary of the research. Among people with chronic infection, about 15% to 25% go on to develop cirrhosis, liver cancer, or other chronic liver disease, usually years or decades later.

Prenatal screening is supposed to catch infected mothers, but it is not universal. About 86% of pregnant people are currently tested for hepatitis B, STAT reported. History also suggests that weakening the general recommendation can reduce vaccination even for babies who are supposed to get it. When the birth dose was paused for babies of negative mothers in 1999, the share of babies born to unscreened mothers who got the vaccine at birth fell from 53% to 7%, even though the advice for those babies had not changed.

"Something can be missed at any step in the care process, so the vaccine dose at birth provides protection," said Dr. Amir Mohareb, an infectious-diseases physician at Massachusetts General Hospital and Harvard Medical School and the study's corresponding author.

Grace Lee, a former committee chair at Stanford University School of Medicine, put the concern more bluntly in an editorial accompanying separate studies: "implementation is not about intent, it is about friction."

What the Models Project

The Annals study simulated babies born in 2026 through age 20, running the model 1,000 times with uncertain inputs varied. Delaying the first dose to 2 months raised chronic infections by 19% compared with the universal birth dose. Under shared decision-making, where coverage by age 2 was assumed to drop to about 50%, chronic infections rose 83%.

The model also projected about 1.8 million young adults a year reaching age 20 still susceptible to hepatitis B under shared decision-making, compared with fewer than 250,000 under the universal birth dose. In every simulation, the birth-dose strategy produced the fewest chronic infections.

Two earlier studies in JAMA Pediatrics reached similar conclusions using different methods. One projected about 76 additional chronic infections and 29 hepatitis B-related deaths per birth cohort from delaying the first dose, plus more than $16 million in added health care costs.

These are models — not observed outcomes. Their results depend on assumptions about screening, vaccine uptake and household exposure. The Annals study did not estimate liver cancer cases or deaths directly. Dr. Norah Terrault, a transplant hepatologist at the USC Keck School of Medicine who was not involved, said it "presents an accurate projection of how the vaccine recommendations may impact future chronic HBV in the U.S."

Questions for Expectant Parents

Parents expecting a baby can ask their obstetrician or midwife whether they have been tested for hepatitis B during pregnancy and what the result was. They can also tell the hospital in advance whether they want the birth dose given, since it is offered in the first 24 hours.

The American Academy of Pediatrics continues to recommend the birth dose for every medically stable newborn, and insurers have said they will keep covering it. Babies born to mothers who test positive should receive both the vaccine and hepatitis B immune globulin within 12 hours of birth.

Anyone with questions about their own infection status, or whether household members have been tested, should talk with a doctor. Hepatitis B often causes no symptoms for years, which is why testing matters.

The bottom line: the universal hepatitis B birth dose remains the operative recommendation while courts review the change. Doctors' central worry is that real-world gaps in screening would leave some newborns exposed, and multiple models project more lifelong infections if the safety net is removed.

What Readers Want to Know

Is the hepatitis B birth dose still recommended? Yes. A March 16, 2026, federal court order paused the change, so the universal birth-dose recommendation remains in effect.

What would the change do? Babies of mothers who test negative would receive the birth dose only after shared decision-making, and those who skip it would start the series at 2 months or later.

Why does infection in infancy matter so much? More than 90% of hepatitis B infections acquired in infancy or early childhood become chronic, raising later risks of cirrhosis and liver cancer.

Why isn't a negative prenatal test enough? Not every pregnant person is tested, results can be missed or wrong, and babies can be exposed after birth by infected household members.

Are the projected increases certain? No. They come from models that depend on assumptions about screening and vaccine uptake.

What should expectant parents do? Confirm your prenatal hepatitis B test result with your provider and discuss the birth dose with your obstetrician or pediatrician before delivery.